Vreeland TJ, Hale DK, Clifton GT, Sears AK, Mittendorf EA and Peoples GE
The goal of vaccine researchers has been induction of a specific and active immune response, which offers patients cancer therapy with limited toxicity and long-standing protection. There have been great strides made toward this goal, as evidenced by the recent FDA approval of Sipuleucel-T (Provenge). The simplest, most efficacious and most affordable vaccine strategy, however, remains an area of great debate. Multiple strategies exist, varying by number and type of target, as well as delivery method. The following review will summarize the most promising strategies for application of the cancer vaccine strategy, focusing on the bright future of peptide-based vaccines.